Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
67Ga-ttTMZ
- Development stage
- Preclinical
- Lead developer
- Texas Therapeutics Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
**67Ga-ttTMZ** is an investigational, tumor-targeted radiochemotherapeutic drug conjugate being developed for somatostatin receptor subtype 2-positive neuroendocrine tumors. It consists of tumor-targeted temozolomide conjugated to the Auger-electron-emitting radionuclide gallium-67. The construct is designed to preferentially localize to SSTR2-positive tumors, where temozolomide-mediated DNA alkylation and localized gallium-67 Auger radiation cooperate to induce DNA damage and apoptosis. Publicly available records identify UTHealth Houston as the originator and classify the program as preclinical for neuroendocrine tumors. ([synapse-patsnap-com.libproxy1.nus.edu.sg](https://synapse-patsnap-com.libproxy1.nus.edu.sg/drug/8bcaad482f7c42d0869eae71cf441a6f))
- Other names
- 67Ga-ttTMZ
02
Targets
SSTR5 (Somatostatin receptor 5)SSTR3 (Somatostatin receptor 3)DNASSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on 67Ga-ttTMZ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 67Ga-ttTMZ.